Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tejpar

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Oncogene|December 22, 1999
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)S Tejpar, F Nollet, C Li, et al.
ESMO Open|October 18, 2023
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II studyS Joris, H Denys, J Collignon, et al.
ESMO Open|May 9, 2026
Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2S Joris, H Denys, J Collignon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabW De Roock, H Piessevaux, J De Schutter, et al.
British Journal of Cancer|January 26, 2013
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patientsV Martin, L Landi, F Molinari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2018
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trialJ K Mooi, P Wirapati, R Asher, et al.
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
British Journal of Cancer|June 13, 2015
Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesisL De Smedt, J Lemahieu, S Palmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2014
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical featuresE Missiaglia, B Jacobs, G D'Ario, et al.
British Journal of Cancer|May 10, 2012
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cellsT Troiani, L Vecchione, E Martinelli, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Oncogene|December 22, 1999
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)S Tejpar, F Nollet, C Li, et al.
ESMO Open|October 18, 2023
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II studyS Joris, H Denys, J Collignon, et al.
ESMO Open|May 9, 2026
Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2S Joris, H Denys, J Collignon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabW De Roock, H Piessevaux, J De Schutter, et al.
British Journal of Cancer|January 26, 2013
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patientsV Martin, L Landi, F Molinari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2018
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trialJ K Mooi, P Wirapati, R Asher, et al.
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
British Journal of Cancer|June 13, 2015
Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesisL De Smedt, J Lemahieu, S Palmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2014
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical featuresE Missiaglia, B Jacobs, G D'Ario, et al.
British Journal of Cancer|May 10, 2012
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cellsT Troiani, L Vecchione, E Martinelli, et al.
Pageof 5